Fabian Lohaus

Fabian Lohaus

Auto-generated profile, based on publicly available information

Fabian Lohaus

Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus TUD Dresden University of Technology Dresden Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2015 in International Journal of Cancer
Verified
Journal Article
Closed access
PBPanagiotis Balermpas
Panagiotis Balermpas
FRFranz Rödel
Franz Rödel
CRClaus Rödel
Claus Rödel
MKMechthild Krause
Mechthild Krause
ALAnnett Linge
Annett Linge
EFEmmanouil Fokas
Emmanouil Fokas


1 July 2016 in Lung Cancer
Verified
Journal Article
Closed access
JRJuliane Rieber
Juliane Rieber
JSJan Streblow
Jan Streblow
LULorenz Uhlmann
Lorenz Uhlmann
MFMichael Flentje
Michael Flentje
MDMarciana Duma
Marciana Duma
MGMatthias Guckenberger
Matthias Guckenberger

1 December 2014 in Radiotherapy and Oncology
Verified
Journal Article
Open access
FLFabian Lohaus
Fabian Lohaus
ALAnnett Linge
Annett Linge
ITInge Tinhofer
Inge Tinhofer
VBVolker Budach
Volker Budach
EGEleni Gkika
Eleni Gkika
MBMichael Baumann
Michael Baumann
To investigate the impact of HPV status in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received surgery and cisplatin-based postoperative radiochemotherapy. For 221 patients with locally advanced squamous cell carcinoma of the hypopharynx, oropharynx or oral cavity treated at the 8 partner sites of the German Cancer Consortium, the impact of HPV DNA, p16 overexpression and p53 expression on outcome were retrospectively analysed. The primary endpoint was loco-regional tumour control; secondary endpoints were distant metastases and overall survival. In the total patient population, univariate analyses revealed a significant impact of HPV16 DNA positivity, p16 overexpression, p53 positivity and tumour site on loco-regional tumour control. Multivariate analysis stratified for tumour site showed that positive HPV 16 DNA status correlated with loco-regional tumour control in patients with oropharyngeal carcinoma (p=0.02) but not in the oral cavity carcinoma group. Multivariate evaluation of the secondary endpoints in the total population revealed a significant association of HPV16 DNA positivity with overall survival (p<0.01) but not with distant metastases. HPV16 DNA status appears to be a strong prognosticator of loco-regional tumour control after postoperative cisplatin-based radiochemotherapy of locally advanced oropharyngeal carcinoma and is now being explored in a prospective validation trial.

31 May 2016 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ALAnnett Linge
Annett Linge
SLSteffen Löck
Steffen Löck
VGVolker Gudziol
Volker Gudziol
ANAlexander Nowak
Alexander Nowak
FLFabian Lohaus
Fabian Lohaus
MKMechthild Krause
Mechthild Krause
Purpose: To investigate the impact of hypoxia-induced gene expression and cancer stem cell (CSC) marker expression on outcome of postoperative cisplatin-based radiochemotherapy (PORT-C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Experimental Design: Expression of the CSC markers CD44, MET, and SLC3A2, and hypoxia gene signatures were analyzed in the resected primary tumors using RT-PCR and nanoString technology in a multicenter retrospective cohort of 195 patients. CD44 protein expression was further analyzed in tissue microarrays. Primary endpoint was locoregional tumor control. Results: Univariate analysis showed that hypoxia-induced gene expression was significantly associated with a high risk of locoregional recurrence using the 15-gene signature (P = 0.010) or the 26-gene signature (P = 0.002). In multivariate analyses, in patients with HPV16 DNA–negative but not with HPV16 DNA–positive tumors the effect of hypoxia-induced genes on locoregional control was apparent (15-gene signature: HR 4.54, P = 0.006; 26-gene signature: HR 10.27, P = 0.024). Furthermore, MET, SLC3A2, CD44, and CD44 protein showed an association with locoregional tumor control in multivariate analyses (MET: HR 3.71, P = 0.016; SLC3A2: HR 8.54, P = 0.037; CD44: HR 3.36, P = 0.054; CD44 protein n/a because of no event in the CD44-negative group) in the HPV16 DNA–negative subgroup. Conclusions: We have shown for the first time that high hypoxia-induced gene expression and high CSC marker expression levels correlate with tumor recurrence after PORT-C in patients with HPV16 DNA–negative HNSCC. After validation in a currently ongoing prospective trial, these parameters may help to further stratify patients for individualized treatment de-escalation or intensification strategies. Clin Cancer Res; 22(11); 2639–49. ©2016 AACR.

1 March 2016 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
MGMatthias Guckenberger
Matthias Guckenberger
Rainer KlementRainer Klement
Rainer Klement
MAMichael Allgäuer
Michael Allgäuer
NANicolaus Andratschke
Nicolaus Andratschke
OBOliver Blanck
Oliver Blanck
FSFlorian Sterzing
Florian Sterzing